News | Hypertension | February 13, 2017

FDA Grants Expedited Access Pathway for MobiusHD to Treat Resistant Hypertension

EAP program designed to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments

February 13, 2017 — Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD device for the treatment of resistant hypertension.

VDI was also one of only nine companies chosen for the FDA’s Early Feasibility Study Investigational Device Exemptions (IDE) Pilot Program in 2012. The Pilot Program enables companies to conduct smaller-scale studies under the guidance of the FDA in the United States in order to meet the requirements for an earlier pathway toward approval.

The EAP program is a focused initiative, recently launched by FDA, to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments. The program was designed for certain medical devices that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases or conditions, such as resistant hypertension, that may be subject to premarket approval applications.

The MobiusHD System, a minimally-invasive system for the treatment of resistant hypertension, capitalizes on the ability of the body’s baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby amplify the body’s natural response to lower blood pressure through vasodilation.

“Among the benefits of the technology are that it may reduce ambulatory blood pressure in resistant hypertension patients who have not benefited from other device or drug based treatments,” said Prof. Brian Williams, co-principal investigator of the CALM II worldwide clinical trial, and NIHR University College London Hospitals Biomedical Research Centre Director. “The Mobius HD technology may provide an important solution for those patients. We are enthusiastic about the product’s potential as we have seen tremendous results in early studies in the U.S. and Europe.”

“In clinical practice, we regularly observe that despite multiple treatment modalities, many patients are still not responding adequately to therapy, whether it be lifestyle changes, multiple drug therapy, or the combination of each. This lack of response significantly increases their risk of further complications,” said Gregg Stone, M.D., co-principal investigator of the CALM II worldwide clinical trial and director of cardiovascular research and education for Columbia University Medical Center/New York-Presbyterian Hospital and co-director of medical research and education at the Cardiovascular Research Foundation.

“The EAP Designation for the MobiusHD device comes at a critical time for hypertension physicians, who are actively looking for treatment options for patients who are not adequately managed with current guideline-directed therapies,” said George Bakris, M.D., chairman of the worldwide CALM II clinical trial hypertension committee and director, ASH Comprehensive Hypertension Center, The University of Chicago School of Medicine.

For more information: www.vasculardynamics.com

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.